Haven Capital Group Inc. Takes Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Haven Capital Group Inc. bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 13,704 shares of the company’s stock, valued at approximately $5,666,000. IDEXX Laboratories makes up approximately 5.3% of Haven Capital Group Inc.’s portfolio, making the stock its 5th largest position.

Several other hedge funds have also recently bought and sold shares of IDXX. William Blair Investment Management LLC lifted its position in shares of IDEXX Laboratories by 701.6% during the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock worth $174,527,000 after purchasing an additional 369,471 shares in the last quarter. Cibc World Markets Corp increased its stake in IDEXX Laboratories by 13.1% during the 4th quarter. Cibc World Markets Corp now owns 14,744 shares of the company’s stock worth $6,096,000 after buying an additional 1,709 shares during the period. Jensen Investment Management Inc. lifted its holdings in IDEXX Laboratories by 11.5% during the 4th quarter. Jensen Investment Management Inc. now owns 9,020 shares of the company’s stock worth $3,729,000 after buying an additional 930 shares in the last quarter. Glenview Trust co boosted its position in IDEXX Laboratories by 152.8% in the 4th quarter. Glenview Trust co now owns 16,812 shares of the company’s stock valued at $6,951,000 after buying an additional 10,162 shares during the period. Finally, Centurion Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 16.4% in the fourth quarter. Centurion Wealth Management LLC now owns 846 shares of the company’s stock worth $350,000 after acquiring an additional 119 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Up 1.7 %

Shares of IDEXX Laboratories stock opened at $422.36 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a fifty day simple moving average of $437.89 and a 200-day simple moving average of $446.30. The stock has a market cap of $34.35 billion, a price-to-earnings ratio of 39.58, a PEG ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent research reports. Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Bank of America lifted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Barclays boosted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.